Chronic Hematologic Toxicity After Peptide Receptor Radionuclide Therapy: An Underrecognized Challenge in Neuroendocrine Tumors
TO THE EDITOR: Peptide receptor radionuclide therapy (PRRT) represents one of the most significant advances in the management of well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Following the pivotal NETTER-1 study ([1][1]), 177Lu-DOTATATE has become the standard second-
Authors
- Davide Campana
- Giuseppe Lamberti
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2026-01-22
- DOI
- https://doi.org/10.2967/jnumed.125.271566
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00